Therapeutic nuclease compositions and methods
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
1. A method for digesting extracellular immune complexes comprising DNA and/or RNA in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and human DNase I operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that the digestion of extracellular immune complexes comprising DNA and/or RNA occurs.
2. The method of claim 1 , wherein the Fc domain is a mutant human IgG1 Fc domain comprising one or more of the mutations selected from P238S, P331S, K322S, N297S, wherein numbering is according to the EU index.
3. The method of claim 1 , wherein the Fc domain comprises a mutant human IgG1 Fc domain comprising a substitution of one or more of three hinge region cysteine residues with serine.
4. The method of claim 1 , wherein the human RNase 1 comprises the amino acid sequence set forth in SEQ ID NO:149, with or without a leader sequence.
5. The method of claim 1 , wherein the Fc domain comprises a human IgG1 Fc domain.
6. The method of claim 1 , wherein the Fc domain is a mutant Fc domain that has reduced binding to Fc receptors on human cells.
7. The method of claim 1 , wherein the Fc domain comprises the amino acid sequence set forth in SEQ ID NO:145.
8. The method of claim 1 , wherein the human DNase I comprises:
(a) the amino acid sequence set forth in SEQ ID NO: 143; or
(b) a G105R mutation as set forth in SEQ ID NO: 142; or
(c) mutations G105R and A114F as set forth in SEQ ID NO: 139.
9. The method of claim 1 , wherein the polypeptide comprises a first linker domain, a second linker domain, or both, wherein when the polypeptide comprises a first linker domain, the human RNase 1 is operatively coupled to the Fc domain by the first linker domain, and when the polypeptide comprises a second linker domain, the human DNase I is operatively coupled to the Fc domain by the second linker domain.
10. The method of claim 9 , wherein the first linker domain, the second linker domain, or both, comprise a gly/ser peptide.
11. The method of claim 9 , wherein the first linker domain, the second linker domain, or both, comprise an NLG peptide comprising the amino acid sequence set forth in SEQ ID NO: 168.
12. A method for digesting extracellular immune complexes comprising DNA and/or RNA in a subject in need thereof, comprising administering to the subject a composition comprising:
(a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153, with or without a leader sequence; or
(b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153, with or without a leader sequence and comprising one or more Fc mutations selected from P238S, P331S, K322S, and N297S, numbering according to EU index; and
a pharmaceutical carrier,
such that the digestion of extracellular immune complexes comprising DNA and/or RNA occurs.
13. The method of claim 12 , wherein the Fc domain comprises a mutant human IgG1 Fc domain comprising a substitution of one or more of three hinge region cysteine residues with serine.
14. A method for digesting extracellular immune complexes comprising DNA and/or RNA in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively linked with or without a linker to the N-terminus of a mutant human IgG1 Fc domain, and human DNase I operatively linked with or without a linker to the C-terminus of the mutant Fc domain, wherein the human RNase 1 comprises the amino acid sequence set forth in SEQ ID NO: 149, with or without a leader sequence, and wherein the human DNase I comprises the amino acid sequence set forth in SEQ ID NO: 139, and wherein the mutant human IgG1 Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that the digestion of extracellular immune complexes comprising DNA and/or RNA occurs.
15. The method of claim 14 , wherein the mutant Fc domain comprises one or more of the mutations selected from P238S, P331S, K322S, and N297S, numbering is according to the EU index.
16. The method of claim 15 , wherein the mutant Fc domain comprises a substitution of one or more of three hinge region cysteine residues with serine.
17. The method of claim 1 , wherein the polypeptide comprises a dimeric polypeptide.
18. The method of claim 1 , wherein the composition is formulated for intravenous administration.
19. A method for treating systemic lupus erythematosus (SLE) in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and human DNase I operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that treatment occurs.
20. A method for treating Sjogren's syndrome in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and human DNase I operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that treatment occurs.
21. The method of claim 19 , wherein the mutant Fc domain comprises one or more of the mutations selected from P238S, P331S, K322S, and N297S, numbering is according to the EU index.
22. The method of claim 21 , wherein the mutant Fc domain comprises a substitution of one or more of three hinge region cysteine residues with serine.
23. The method of claim 19 , wherein the polypeptide comprises a dimeric polypeptide.
24. The method of claim 19 , wherein the composition is formulated for intravenous administration.
25. The method of claim 20 , wherein the mutant Fc domain comprises one or more of the mutations selected from P238S, P331S, K322S, and N297S, numbering is according to the EU index.
26. The method of claim 25 , wherein the mutant Fc domain comprises a substitution of one or more of three hinge region cysteine residues with serine.
27. The method of claim 20 , wherein the polypeptide comprises a dimeric polypeptide.
28. The method of claim 20 , wherein the composition is formulated for intravenous administration.